Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL31119163 | 0.97 | TSHR (0.46) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL1527604 | 0.83 | TSHR (0.48) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL12106799 | 0.79 | TSHR (0.43) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL22639014 | 0.79 | TSHR (0.43) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL14827441 | 0.77 | TSHR (0.42) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL17228535 | 0.77 | TSHR (0.42) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL10911354 | 0.77 | TSHR (0.53) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL12456032 | 0.76 | — | — | |
| SCHEMBL13779263 | 0.75 | TSHR (0.40) | TSHRTP53TDP1POLBCYP3A4 | |
| SCHEMBL10201143 | 0.74 | TSHR (0.50) | TSHRTP53TDP1POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264651-A1 | ELECTROLYTE AND LITHIUM ION BATTERIES MADE THEREWITH | WILDCAT DISCOVERY TECHNOLOGIES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| US-20240290966-A1 | NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) | 2024-08-29 | — | — | US | claimed |
| EP-3784649-B1 | PROCESS FOR THE SYNTHESIS OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID | UNIV NORTHWESTERN (US) | 2024-07-31 | — | — | EP | claimed |
| EP-4366014-A1 | NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Panasonic Intellectual Property Management Co., Ltd. (JP) | 2024-05-08 | — | — | EP | claimed |
| CN-115286667-B | Alpha-galactosyl ceramide analogue, and preparation method and application thereof | 华中农业大学 | 2024-03-26 | — | — | CN | claimed |
| WO-2023276526-A1 | NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | パナソニックＩＰマネジメント株式会社 | 2023-01-05 | — | — | WO | claimed |
| CN-115286667-A | Alpha-galactosyl ceramide analogue and preparation method and application thereof | 华中农业大学 | 2022-11-04 | — | — | CN | claimed |
| CN-108064427-A | For the electrolyte preparations of lithium ion battery | 野猫技术开发公司 | 2018-05-22 | — | — | CN | claimed |
| EP-2767541-A1 | LPA receptor agonists and antagonists | Rxbio, Inc. (US) | 2014-08-20 | — | — | EP | claimed |
| EP-0815120-B1 | 17-DIFLUOROMETHYLENE-OESTRATRIENES | SCHERING AG (DE) | 2001-02-14 | — | — | EP | claimed |
| US-6018062-A | SUCH AS 17-DIFLUOROMETHYLENE-ESTRA-1,3,5(10)-TRIEN-3-OL; USE AS ANTIOXIDANTS AND VASCULOPROTECTIVE AGENTS AS THEY CAUSE VASODILATOR NITROGEN OXIDE RELEASE AND PREVENT OXIDATION OF LDL CHOLESTEROL | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-01-25 | — | — | US | claimed |
| EP-0815120-A1 | 17-DIFLUOROMETHYLENE-OESTRATRIENES | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-01-07 | — | — | EP | claimed |
| WO-1996028462-A1 | 17-DIFLUOROMETHYLENE-OESTRATRIENES | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-09-19 | — | — | WO | claimed |
| US-20260135164-A1 | LITHIUM SECONDARY BATTERIES CAPABLE OF SELF-POISONING | PROLOGIUM TECHNOLOGY CO., LTD. (TW) | 2026-05-14 | — | — | US | disclosed |
| US-12620623-B2 | Electrolyte additive, electrolyte for batteries including electrolyte additive, and secondary battery including electrolyte | SOULBRAIN CO., LTD. (KR) | 2026-05-05 | — | — | US | disclosed |
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-4871721-A | HYPOCHOLESTEROLEMIC AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0331550-A1 | Novel aspartate transcarbamylase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0328834-A1 | Novel aspartate transcarbamylase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-23 | — | — | EP | disclosed |
| US-4567000-A | ANTIFERTILITY AGENTS | THE UPJOHN COMPANY (US) | 1986-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260135164-A1 | LITHIUM SECONDARY BATTERIES CAPABLE OF SELF-POISONING | L3MBTL3, HAO2, LDHB | TSHR 3143/4885TP53 553/4885TDP1 1369/4885 |
| US-12620623-B2 | Electrolyte additive, electrolyte for batteries including electrolyte additive, and secondary battery including electrolyte | KCNN2, KCNN1, KCNN3 | TSHR 3766/4885TP53 1906/4885TDP1 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.